Systems and methods for spectral analysis of a tissue mass using an instrument, an optical probe, and a Monte Carlo or a diffusion algorithm

US9820655B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9820655-B2
Application numberUS-68030508-A
CountryUS
Kind codeB2
Filing dateSep 29, 2008
Priority dateSep 28, 2007
Publication dateNov 21, 2017
Grant dateNov 21, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Systems and methods for spectral analysis of a tissue mass using an instrument, an optical probe, and a Monte Carlo algorithm or a diffusion algorithm are provided. According to one method, an instrument is inserted into a tissue mass. A fiber optic probe is applied via the instrument into the tissue mass. Turbid spectral data of the tissue mass is measured using the fiber probe. The turbid spectral data is converted to absorption, scattering, and/or intrinsic fluorescence spectral data via a Monte Carlo algorithm or diffusion algorithm. Biomarker concentrations in the tissue mass are quantified using the absorption, scattering, and/or intrinsic fluorescence spectral data.

First claim

Opening claim text (preview).

What is claimed is: 1. A system for determining biomarker concentrations in a tissue mass, the system comprising: an instrument for inserting into the tissue mass; a fiber optic probe for interfacing the tissue mass upon being inserted into the instrument and measuring turbid spectral data of the tissue mass, wherein measuring the turbid spectral data includes conducting fluorescence spectral measurements and diffuse reflectance measurements of the tissue mass simultaneously, wherein the fiber optic probe is a forward firing fiber optic probe that includes a probe tip comprising a plurality of centrally grouped illumination fibers that are concentrically surrounded by a plurality of collection fiber rings, wherein each of the collection fiber rings consists of a plurality of ring-specific collection fibers or a plurality of ring-specific collection fibers and a plurality of dead fibers; and a processing unit for converting the turbid spectral data to absorption, scattering, and intrinsic fluorescence spectral data via a Monte Carlo algorithm or a diffusion algorithm and quantifying biomarker concentrations in the tissue mass using the absorption, scattering, and intrinsic fluorescence spectral data, wherein the intrinsic fluorescence spectral data is corrected to account for the absorption and scattering data. 2. The system of claim 1 wherein the fiber optic probe fits within a biopsy needle or a biopsy cannula. 3. The system of claim 2 wherein the biopsy needle includes at least one of a Suros 9G biopsy needle, a Mammotome biopsy needle, a Bard Vacora 10G biopsy needle, a Bard Vacora 14G biopsy needle, and a Cardinal Achieve 14G biopsy needle. 4. The system of claim 1 wherein the instrument comprises a cannula, a biopsy needle, an endoscopic instrument, and a laparoscopic instrument. 5. The system of claim 1 wherein the turbid spectral data comprises diffuse reflectance spectral data and fluorescence spectral data of the tissue mass. 6. The system of claim 1 wherein the biomarker concentrations are used to determine if the tissue mass is malignant, benign, or normal, or are used to quantify drug uptake by the tissue mass. 7. The system of claim 6 wherein a biopsy is conducted on the tissue mass through a cannula or a biopsy needle if the tissue is malignant. 8. The system of claim 1 wherein the fiber optic probe is adapted to acquire the turbid spectral data using a spectrometer having a spectral bandpass of between about 2.5 nm and 5 nm. 9. The system of claim 1 wherein the Monte Carlo algorithm includes either an inverse Monte Carlo reflectance algorithm or an inverse Monte Carlo fluorescence algorithm. 10. The system of claim 1 wherein the processing unit is further configured to determine the concentrations at least one of total hemoglobin, oxyhemoglobin concentration, deoxyhemoglobin concentration, beta carotene concentration, hemoglobin saturation, nicotinamide adenine dinucleotide (NADH), flavin adenine dinucleotide (FAD), collagen, porphyrins, retinol, tryptophan, tissue blood loss, dilutional effects of fluids, in vivo. 11. A method for determining biomarker concentrations in a tissue mass, the method comprising: inserting an instrument into the tissue mass; applying a fiber optic probe upon being inserted into the instrument into the tissue mass, wherein the fiber optic probe is a forward firing fiber optic probe that includes a probe tip comprising a plurality of centrally grouped illumination fibers that are concentrically surrounded by a plurality of collection fiber rings, wherein each of the collection fiber rings consists of a plurality of ring-specific collection fibers or a plurality of ring-specific collection fibers and a plurality of dead fibers; measuring turbid spectral data of the tissue mass using the fiber optic probe, wherein measuring the turbid spectral data includes conducting fluorescence spectral measurements and diffuse reflectance measurements of the tissue mass simultaneously; converting the turbid spectral data to absorption, scattering, and intrinsic fluorescence spectral data via a Monte Carlo algorithm or a diffusion algorithm; and quantifying biomarker concentrations in the tissue mass using the at least one of absorption, scattering, and intrinsic fluorescence spectral data, wherein the intrinsic fluorescence spectral data is corrected to account for the absorption and scattering data. 12. The method of claim 11 wherein the fiber optic probe is adapted to fit within a biopsy needle or a biopsy cannula. 13. The method of claim 12 wherein the biopsy needle includes at least one of a Suros 9G biopsy needle, a Mammotome biopsy needle, a Bard Vacora 10G biopsy needle, a Bard Vacora 14G biopsy needle, and a Cardinal Achieve 14G biopsy needle. 14. The method of claim 11 wherein the instrument comprises a cannula, a biopsy needle, an endoscopic instrument, and a laparoscopic instrument. 15. The method of claim 11 wherein the turbid spectral data comprises diffuse reflectance spectral data and fluorescence spectral data of the tissue mass. 16. The method of claim 11 wherein the biomarker concentrations are used to determine if the tissue mass is malignant, benign, or normal, or are used to quantify drug uptake by the tissue mass. 17. The method of claim 16 wherein a biopsy is conducted on the tissue mass through a cannula or a biopsy needle if the tissue is malignant. 18. The method of claim 11 wherein the fiber optic probe is adapted to acquire the turbid spectral data using a spectrometer having a spectral bandpass of between about 2.5 nm and 5 nm. 19. The method of claim 11 wherein the Monte Carlo algorithm includes either an inverse Monte Carlo reflectance algorithm or an inverse Monte Carlo fluorescence algorithm. 20. The method of claim 11 further comprising: applying a contrast agent to the tissue mass to enhance light scattering, absorption, or fluorescence in the tissue mass. 21. The method of claim 20 wherein the enhanced light scattering, absorption, or fluorescence aids with margin assessment. 22. The method of claim 20 wherein the contrast agent includes at least one of acetic acid, Acriflavin, 2-2-deoxy-D-glucose (NBDG), fluorescin, aminolevulinic acid, and methylene blue. 23. The method of claim 11 wherein the processing unit is further configured to determine the concentrations at least one of total hemoglobin, oxyhemoglobin concentration, deoxyhemoglobin concentration, beta carotene concentration, nicotinamide adenine dinucleotide (NADH), flavin adenine dinucleotide (FAD), collagen, retinol, porphyrin, hemoglobin saturation, tissue blood loss, dilutional effects of fluids in vivo.

Assignees

Inventors

Classifications

  • by spectroscopy, i.e. measuring spectra, e.g. Raman spectroscopy, infrared absorption spectroscopy (A61B5/0071 takes precedence) · CPC title

  • for introduction into the body, e.g. by catheters (A61B5/1459 takes precedence) · CPC title

  • using infrared radiation · CPC title

  • by measuring fluorescence emission · CPC title

  • Monitoring transplanted tissue or organ, e.g. for possible rejection reactions after a transplant · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9820655B2 cover?
Systems and methods for spectral analysis of a tissue mass using an instrument, an optical probe, and a Monte Carlo algorithm or a diffusion algorithm are provided. According to one method, an instrument is inserted into a tissue mass. A fiber optic probe is applied via the instrument into the tissue mass. Turbid spectral data of the tissue mass is measured using the fiber probe. The turbid spe…
Who is the assignee on this patent?
Ramanujam Nirmala, Yu Bing, Brown Jonathon Quincy, and 1 more
What technology area does this patent fall under?
Primary CPC classification A61B5/0091. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Nov 21 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).